An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab

Tali Shafat*, Daniel Grupel, Tzvika Porges, Ran Abuhasira, Ana Belkin, Ofir Deri, Yonatan Oster, Shadi Zahran, Ehud Horwitz, Netanel A. Horowitz, Hazim Khatib, Marjorie Vieira Batista, Anita Cassoli Cortez, Tal Brosh-Nissimov, Yafit Segman, Linor Ishay, Regev Cohen, Alaa Atamna, Amy Spallone, Roy F. ChemalyJuan Carlos Ramos-Ramos, Michal Chowers, Evgeny Rogozin, Noga Carmi Oren, Şiran Keske, Orit Wolfovitz Barchad, Lior Nesher

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Keyphrases

Medicine and Dentistry